European Companies Search Engine
EU funding (€8,646,254): Evaluation of ratioNally Designed Influenza vaccines Hor12 Feb 2020 EU Research and Innovation programme "Horizon"
Overview
Text
Evaluation of ratioNally Designed Influenza vaccines
ENDFLU will develop three complementary next-generation influenza vaccination strategies for the world, fueled by the unique combined expertise of Indian and European partners in rational vaccine design and development: • Create a repository of pre-pandemic GMP-compliant MVA-based vaccine seeds, each encoding an influenza hemagglutinin (HA), based on European partners demonstration of clinical safety and cross-clade immunogenicity of MVA-H5. • Optimize and select protein- and MVA-based constructs developed by Indian and European ENDFLU partners, resulting in a rationally combined vaccine formulation that induces broadly protective humoral and cell-mediated immunity against all influenza manifestations. This will be advanced in a Phase I clinical trial and Controlled Human Infection Model (CHIM) study. • Pre-clinically advance other promising protein- and MVA-based constructs toward future development beyond ENDFLU. Constructs to elicit humoral immunity build on rationally-designed and optimized conserved epitopes of influenza surface proteins, HA stem- and HA head-nanoparticles, and NA-M2e fusions either as proteins or MVA expressed. Other MVA-based constructs to elicit cell-mediated immunity will encode conserved internal protein T cell epitopes, as an artificial polyepitope. The best candidates will be selected based on biochemical, biophysical, functional and manufacturing criteria, and immunogenicity and protective efficacy in mice and ferrets. The selected protein-based construct will enter a Part A Phase I clinical trial in India assessing safety, immunogenicity and optimal dose, to be combined with the selected MVA-based construct. This protein-MVA combination will enter a Part B Phase I clinical trial in the EU, assessing safety and immunogenicity, followed by the CHIM study. A dissemination and exploitation plan, and collaboration with key scientific advocacy organizations will facilitate the adoption of ENDFLU achievements to combat influenza worldwide.
Funded Companies:
| Company name | Funding amount |
| Council OF Scientific AND Industrial Research | €0.00 |
| CR2O B.V. | €3,364,572 |
| ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE | €300,000 |
| Indian Institute OF Science | €0.00 |
| Indian Institute OF Science Education AND Research Thiruvananthapuram | €0.00 |
| LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN | €2,342,075 |
| Lunds Universitet | €360,925 |
| Manipal Academy OF Higher Education | €0.00 |
| Mynvax Ltd. | €0.00 |
| Seth GSM College AND KEM Hospital Diamond Jubilee Society | €0.00 |
| STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER | €1,234,225 |
| Translational Health Science AND Technology Institute | €0.00 |
| UNIVERSITEIT UTRECHT | €435,708 |
| VIB VZW | €608,750 |
Source: https://cordis.europa.eu/project/id/874650
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "Council OF Scientific AND Industrial Research - EU funding (€8,646,254): Evaluation of ratioNally Designed Influenza vaccines"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
